TriSalus Life Sciences Files 8-K on Jan 24 Event
Ticker: TLSIW · Form: 8-K · Filed: Jan 25, 2024 · CIK: 1826667
| Field | Detail |
|---|---|
| Company | Trisalus Life Sciences, Inc. (TLSIW) |
| Form Type | 8-K |
| Filed Date | Jan 25, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $11.50, $9.28 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-event, 8-K, filing
TL;DR
**TriSalus Life Sciences filed an 8-K on Jan 24, signaling a potentially significant corporate event.**
AI Summary
TriSalus Life Sciences, Inc. filed an 8-K on January 25, 2024, reporting an event that occurred on January 24, 2024. This filing is a 'Current Report' under Section 13 or 15(d) of the Securities Exchange Act of 1934. The company, based in Westminster, Colorado, previously operated as MedTech Acquisition Corp. This matters to investors as 8-K filings often signal significant corporate events, and understanding the nature of this specific event (which is not fully detailed in the provided snippet) is crucial for assessing potential impacts on the stock.
Why It Matters
8-K filings are used to announce major events that shareholders should know about, potentially impacting the company's stock price and future outlook. Investors need to understand the specific event reported to assess its implications.
Risk Assessment
Risk Level: medium — The filing indicates a significant event occurred, but without details, the specific impact and risk are unknown, creating uncertainty.
Analyst Insight
A smart investor would monitor for subsequent filings or press releases from TriSalus Life Sciences, Inc. that provide specific details about the event reported on January 24, 2024, before making any investment decisions.
Key Numbers
- 001-39813 — Commission File Number (identifies the company's registration with the SEC)
- 85-3009869 — I.R.S. Employer Identification No. (identifies the company for tax purposes)
- 888-321-5212 — Registrant’s telephone number (contact information for the company)
Key Players & Entities
- TriSalus Life Sciences, Inc. (company) — registrant filing the 8-K
- MedTech Acquisition Corp (company) — former name of TriSalus Life Sciences, Inc.
- January 24, 2024 (date) — date of the earliest event reported
- January 25, 2024 (date) — date the 8-K was filed
- Delaware (company) — state of incorporation for TriSalus Life Sciences, Inc.
- Westminster, Colorado (company) — principal executive offices location for TriSalus Life Sciences, Inc.
Forward-Looking Statements
- Further details regarding the specific event reported on January 24, 2024, will be disclosed, potentially impacting stock volatility. (TriSalus Life Sciences, Inc.) — medium confidence, target: Q1 2024
FAQ
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant as specified in its charter is TRISALUS LIFE SCIENCES, INC.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 24, 2024.
What was the former name of TriSalus Life Sciences, Inc.?
The former name of TriSalus Life Sciences, Inc. was MedTech Acquisition Corp, with the name change occurring on September 30, 2020.
Where are the principal executive offices of TriSalus Life Sciences, Inc. located?
The principal executive offices of TriSalus Life Sciences, Inc. are located at 6272 W. 91st Ave., Westminster, Colorado, 80031.
Under which sections of the Securities Exchange Act of 1934 is this Current Report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-01-25 17:19:33
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share TLSI Nasdaq Glo
- $11.50 — of Common Stock at an exercise price of $11.50 per share TLSIW Nasdaq Global Marke
- $9.28 — tion has an exercise price per share of $9.28 and will vest as to 25% of the shares o
Filing Documents
- tm244105d1_8k.htm (8-K) — 26KB
- 0001104659-24-006749.txt ( ) — 239KB
- tlsi-20240124.xsd (EX-101.SCH) — 3KB
- tlsi-20240124_def.xml (EX-101.DEF) — 26KB
- tlsi-20240124_lab.xml (EX-101.LAB) — 36KB
- tlsi-20240124_pre.xml (EX-101.PRE) — 25KB
- tm244105d1_8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TRISALUS LIFE SCIENCES, INC. By: /s/ Mary Szela Mary Szela Chief Executive Officer Dated: January 25, 2024